Retatrutide Real-World Side Effects: What 13,589 Reddit Users Reported

The Study: What 13,589 Reddit Users Reported

On June 3, 2026, a team from the University of Pennsylvania — Neil K. R. Sehgal, Jena Shaw Tronieri, Benjamin Rader, Lyle Ungar, and Sharath Chandra Guntuku — posted a preprint on medRxiv titled Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. It is, as far as we are aware, the first systematic characterization of what people taking gray-market retatrutide actually report experiencing, and its central finding is genuinely surprising.

The researchers collected Reddit posts and comments from May 1, 2021 through December 31, 2025, drawing on six retatrutide-specific communities and twenty-one broader peptide, exercise, and weight-management subreddits. After filtering out deleted content, bot accounts, and low-quality text, they retained 148,640 retatrutide-related posts and comments from 38,936 unique users. A large language model classifier then identified which authors were describing their own personal use of retatrutide — as opposed to discussing it abstractly, asking questions, or talking about someone else.

That classifier flagged 45,592 posts and comments from 13,589 unique users reporting current retatrutide use, with the relevant content dated from March 10, 2023 through the end of 2025. A second model extracted the symptoms each author attributed to the drug and mapped them onto the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms — the same standardized vocabulary that regulators use to code adverse events. Among the 13,589 users, 9,699 (71.4 percent) had at least one extractable symptom concept. After the authors deliberately excluded weight-loss outcomes and appetite-suppression terms — because those are the intended effect, not adverse events — 7,823 users (57.6 percent) still had at least one mapped symptom, and that group formed the denominator for the symptom-frequency analysis.

The method is not casual text-mining. The authors validated both models against manual human review of 100 posts each. The self-use classifier achieved 94.4 percent precision and 97.1 percent recall; the symptom-extraction model achieved 91.0 percent positive predictive value and 98.6 percent recall after the prespecified exclusions. Those are strong validation numbers for natural-language work of this kind, which is part of why the result deserves to be taken seriously rather than dismissed as Reddit noise.

What Retatrutide Is and Why the Trial Profile Differs

Retatrutide is an investigational once-weekly injectable developed by Eli Lilly. Its distinguishing feature is that it is a triple agonist — it simultaneously activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That third target, the glucagon receptor, is what sets it apart from the drugs most people already know. Semaglutide (Ozempic, Wegovy) is a single GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist. Retatrutide is the only tri-agonist in late-stage obesity development, and the glucagon component is both the source of its potency and, plausibly, the source of its distinctive symptom profile.

In the phase 2 obesity trial published in the New England Journal of Medicine in 2023 (Jastreboff and colleagues), retatrutide produced striking weight loss — up to roughly a quarter of body weight at the highest dose over forty-eight weeks — and its adverse-event profile looked like the rest of the incretin class: nausea, diarrhea, vomiting, and constipation were the most common events, generally mild to moderate and concentrated during dose escalation. If you only knew the trial data, you would expect the dominant real-world complaint to be nausea. The Reddit data says otherwise, and the gap between the two is the whole point of the new study.

It is worth being clear about why a controlled trial and a Reddit cohort can produce such different pictures of the same molecule. The trial enrolls screened participants, uses pharmaceutical-grade drug at known doses with structured titration, monitors systematically with standardized adverse-event questionnaires, and follows everyone whether or not they have anything to report. The Reddit population self-selects, uses unregulated product of unknown dose and purity, escalates on their own schedules, frequently stacks other compounds, and only generates data when someone chooses to write a post. Those are not small differences. They mean the two datasets are answering subtly different questions — and that divergence is informative in its own right.

Public interest in retatrutide has exploded over exactly the period the data covers. The authors note that in U.S. Google Trends data, relative search interest for retatrutide rose from near zero before mid-2023 to more than three-quarters of semaglutide's search interest by April 2026. A compound that barely existed in public consciousness two years ago is now nearly as searched as the most famous weight-loss drug in the world — and almost all of that real-world use is happening outside any regulated prescribing pathway.

Trial Side Effects vs Real-World Reports: The Divergence

The cleanest way to see the finding is to lay the two profiles side by side. The phase 2 trial column reflects the published Jastreboff data; the Reddit column reflects the rank order of self-reported symptoms in the new analysis, after the authors removed the intended weight-loss and appetite-suppression effects.

The authors went one step further and compared the retatrutide symptom categories against their own prior published work on semaglutide and tirzepatide Reddit reports. The contrast held up: retatrutide discussions were more concentrated in appetite, general-system, muscle-related, sleep, and heart-rate or pulse categories, whereas semaglutide and tirzepatide discussions were more concentrated in nausea, vomiting, and gastrointestinal-motility categories. This is a comparison of two different Reddit cohorts rather than a head-to-head trial, and the authors are careful to call it descriptive — the samples were not matched on demographics or clinical characteristics and no statistical tests were run. But the pattern is consistent: retatrutide's real-world fingerprint looks different from the rest of the class, in a direction that points at its unique pharmacology.

Why Appetite Increase, Not Suppression? The Glucagon Question

The single most counterintuitive result is that increased appetite and food craving top the list of self-reported symptoms for a drug whose entire purpose is to suppress appetite. Several explanations are plausible, none is proven, and the study itself is explicit that it cannot adjudicate between them. It is worth walking through them because each carries a different practical implication.

The glucagon component. Glucagon-receptor agonism is the feature that distinguishes retatrutide from the rest of the class, and glucagon biology is genuinely complex. Glucagon raises energy expenditure and mobilizes hepatic glucose, which is part of how retatrutide drives such large weight loss. But glucagon's effects on hunger are not cleanly suppressive in the way GLP-1's are, and the net effect on subjective appetite of simultaneously hitting three receptors with different and partly opposing metabolic roles is not something trial-average data captures well at the individual level. Some users describing returning hunger may be experiencing the genuine pharmacology of a tri-agonist that does not flatten appetite as uniformly as a pure GLP-1 drug.

Under-dosing and the trough effect. Gray-market users are not titrating to trial-defined therapeutic exposures under supervision. Some are deliberately micro-dosing; some are using less-potent or mislabeled product; some are spacing doses out to stretch supply. A weekly compound that is dosed too low, or whose effect wanes before the next injection, can produce a real subjective rebound in hunger in the back half of the week — an experience a trial participant on a properly titrated dose might never have. The appetite-increase signal may, in part, be a signal about dosing behavior rather than about the molecule's intrinsic effect.

Reporting and contrast bias. People on a weight-loss drug expect their appetite to disappear. When it instead returns, that violation of expectation is salient and postable in a way that "my appetite is still suppressed, as designed" is not. The forums systematically over-collect the surprising experience. This does not mean the appetite reports are fabricated — only that their prominence in the ranking is partly an artifact of what people choose to write down.

Product identity. The study cannot verify that any given user injected actual retatrutide. Gray-market vials labeled "retatrutide" have unknown contents. A subset of the appetite-increase reports could reflect under-potent or incorrect product. This is not a fringe concern: the FDA issued a warning in February 2026 specifically about unapproved GLP-1 products, including retatrutide, being sold directly to consumers and frequently labeled "for research" or "not for human consumption."

Fatigue, Increased Energy, and the Tri-Agonist Metabolism

The second oddity is that fatigue and increased energy both appear high on the list — seemingly contradictory experiences reported by different users of the same drug. This is less paradoxical than it first looks once you separate the populations.

Fatigue is a recognized accompaniment of rapid weight loss and reduced caloric intake regardless of the agent driving it. When the body is running a large energy deficit, tiredness is expected, and retatrutide drives some of the steepest weight loss in the class. Layer on the dehydration and electrolyte shifts that come with reduced intake and any gastrointestinal losses, and fatigue becomes a predictable companion of effective dosing. Some fraction of the fatigue reports are simply the metabolic cost of losing weight quickly.

Increased energy, reported by a different slice of users, plausibly tracks the glucagon-driven rise in energy expenditure and hepatic glucose mobilization, which can feel like stimulation. It may also reflect the user base. Retatrutide is popular among people who lift and train, and a compound that is improving body composition and metabolic flexibility in a fitness-oriented user can produce a subjective sense of being more energetic and capable in the gym. The same molecule, in two different people with two different baselines and goals, generates opposite-sounding reports — and a forum captures both.

For context on how these metabolic effects are supposed to work and what the trial evidence actually supports, our retatrutide mechanism guide and research summary walk through the pharmacology in more depth.

Insomnia and Elevated Heart Rate: The Stimulatory Signal

Insomnia and elevated heart rate sitting high in the rankings is the part of the profile that most deserves attention, because these are the symptoms that connect to a real safety question rather than to comfort.

Across the incretin class there is a recognized, generally modest increase in resting heart rate, attributed to autonomic and direct cardiovascular effects. In the controlled trial setting this is a measured mean shift of a few beats per minute, usually clinically unremarkable in screened participants. In a self-reporting population using unverified product at uncertain doses, "my heart rate is up" and "palpitations" become things people notice and post about — and the glucagon component, which raises metabolic rate and can affect cardiovascular parameters, adds a mechanistic reason the tri-agonist might push this harder than a pure GLP-1 drug.

Insomnia plausibly rides along with the same stimulatory axis: increased energy expenditure, a higher resting heart rate, and a generally more activated metabolic state are not a recipe for easy sleep. Some users may also be dosing at times of day that interact poorly with sleep, or experiencing the sleep disruption that can accompany rapid weight loss and altered eating patterns.

Muscle-Related Symptoms and the Weightlifter Cohort

One of the more distinctive features of the retatrutide Reddit profile, relative to the semaglutide and tirzepatide comparison, was a greater concentration of muscle-related symptoms. There are several non-exclusive readings, and they matter because muscle is the tissue everyone is most anxious about losing on these drugs.

First, the user base skews toward people who lift, who are unusually attuned to anything happening to their muscles — cramps, soreness, perceived loss of fullness or strength — and who will post about it. A bodybuilding-adjacent population reporting more muscle symptoms than a general weight-loss population is partly a reflection of who is doing the reporting and what they care about.

Second, rapid weight loss of any cause carries a real risk of lean-mass loss, and retatrutide drives weight loss at the high end of the class. Muscle symptoms in a fast-loss context can reflect genuine catabolic stress, inadequate protein intake, or electrolyte disturbances — cramps in particular track with the magnesium, potassium, and sodium shifts that accompany reduced intake and gastrointestinal losses. We cover this concern specifically in our retatrutide muscle-loss overview.

Third, the stacking problem. People in these communities frequently run multiple compounds at once, and a muscle symptom attributed to retatrutide could belong to something else entirely in the stack. The study has no way to disentangle this, which is one of its most important limitations and the subject of the next section.

The Gray-Market Variables: Dose, Purity, and Stacking

Everything above has to be read through the lens of how this population actually uses the compound, because the conditions of use are radically different from a clinical trial and they contaminate every symptom report in ways that cannot be cleanly separated out.

Unknown identity and purity. Gray-market retatrutide is sold as lyophilized powder by vendors operating outside pharmaceutical regulation. There is no guarantee the vial contains retatrutide, contains the labeled amount, or is free of synthesis impurities and endotoxin. A symptom blamed on retatrutide could be a reaction to a contaminant, to residual solvent, or to a different peptide entirely. The study's authors list product quality and dose variability first among their candidate explanations for the divergent profile.

Reconstitution and dosing error. Users reconstitute powder themselves with bacteriostatic water and calculate their own doses. Errors of an order of magnitude are not rare in self-administered peptide use, and a mis-measured dose produces effects that have nothing to do with the molecule's true profile at its intended exposure. Our reconstitution guide and dosing overview exist precisely because this is where the most consequential mistakes happen.

Polypharmacy and stacking. Concurrent use of multiple unapproved peptides is the norm, not the exception, in these communities. A user running retatrutide alongside a growth-hormone secretagogue, a healing peptide, and a stimulant pre-workout has no way of knowing which compound produced a given symptom — and neither does a text-mining study reading their post. The authors name stacking explicitly as a confound.

Population. The trial enrolled people with obesity under medical screening. The Reddit population includes lean recreational users, weightlifters using it for body recomposition, and people with undisclosed medical histories and medications. A symptom profile from this group is not transferable to the trial population or to a hypothetical approved-prescribing population.

Why Reddit Data Is Both Valuable and Limited

It would be a mistake to either dismiss this study as "just Reddit" or to over-read it as a measured side-effect rate. Its value and its limits are both specific, and the authors are unusually clear-eyed about both.

The value is that it provides the only available window into a population that is otherwise invisible to safety surveillance. People buying unapproved retatrutide online do not show up in clinical-trial databases or, usually, in spontaneous adverse-event reporting systems. Their experiences exist mostly as forum posts, and a validated pipeline that can read 148,640 of those posts and extract structured symptom data is a real contribution to pharmacovigilance. The headline divergence from the trial profile is a legitimate hypothesis-generating signal that the authors argue warrants formal attention.

The limits are equally real. Reddit users are not a representative sample of retatrutide users, let alone of the broader population. People who experience side effects are more likely to post than people who do not, which inflates the apparent prominence of adverse experiences. The analysis cannot determine product identity, purity, dose, route, treatment duration, concurrent drugs, or medical history. Critically, it cannot estimate incidence — it tells you what is reported, in what relative order, not how often any effect happens per user or per dose. It cannot establish causation, dose-response, or comparative safety against approved drugs. And natural-language extraction, even validated, can misattribute or miss symptoms.

What This Means If You're Researching Retatrutide

For anyone reading about retatrutide in a research-and-education context, the practical takeaways from this study are modest but real.

The first is that the trial side-effect list is not the whole story for how this compound behaves in unregulated real-world use. If your mental model of retatrutide was "it's like Ozempic but stronger, so expect nausea," this data complicates that. The real-world reports cluster in appetite, energy, sleep, and heart-rate categories that the trial framing would not lead you to anticipate, and at least some of that is plausibly the genuine pharmacology of a glucagon-containing tri-agonist rather than an artifact.

The second is that the heart-rate and insomnia signals are the ones that connect to actual risk, and they are the ones least likely to be pure reporting bias because they have a clear mechanistic basis. A persistently elevated resting heart rate is not a nuisance symptom to ignore, particularly with unverified product and any cardiovascular history.

The third, and most important, is that the entire dataset is downstream of gray-market use — unknown product, self-calculated doses, frequent stacking. The single largest driver of unpredictable effects in this population is not retatrutide's pharmacology at all; it is the unregulated supply chain and self-administration. The compound remains investigational and unapproved, with no established safety margin in the population actually using it. If you have any cardiovascular, metabolic, or psychiatric condition, or take other medications, the risks here are not merely uncharacterized — they are uncharacterizable from data like this. For the broader picture of what is and is not known, see our retatrutide safety overview and the cross-compound view in retatrutide vs tirzepatide.

Research-Grade Sourcing When Variables Matter

This study is, at its core, an argument about how much uncertainty unregulated sourcing injects into everything downstream. When a symptom cannot be cleanly attributed because the product itself is an unknown, vendor quality stops being a footnote and becomes the dominant variable. The vendors below publish independent, batch-specific HPLC certificates of analysis — the minimum bar for reducing one of the largest confounds the Penn researchers identified. Affiliate links — we earn a small commission at no extra cost to you. See our affiliate disclosure for details.

Frequently Asked Questions

What did the 2026 Reddit retatrutide study actually find?

A University of Pennsylvania team led by Neil Sehgal and Sharath Guntuku analyzed 148,640 retatrutide-related Reddit posts and comments and identified 13,589 users self-reporting current use. After excluding weight-loss and appetite-suppression terms, 7,823 users had at least one mapped symptom. Unlike the phase 2 obesity trial, where gastrointestinal events like nausea, diarrhea, vomiting, and constipation dominated, the most commonly reported real-world symptoms were increased appetite, fatigue, increased energy, nausea, food craving, insomnia, and elevated heart rate. The authors stress the findings are hypothesis-generating, not a measure of how often these effects occur.

Why would retatrutide increase appetite when it is a weight-loss drug?

Increased appetite and food craving topping the real-world list is the most counterintuitive finding. Several non-exclusive explanations are plausible. Retatrutide is a triple agonist that includes glucagon receptor activity, and glucagon signaling has complex effects on energy expenditure and intake. Gray-market dosing is unregulated, so some users may be under-dosing relative to the trial's appetite-suppressing levels, or experiencing rebound hunger as a weekly dose wears off. Reconstitution and potency variability in unapproved product means the actual delivered dose is uncertain. And users who notice their appetite returning are more likely to post about it. None of these is proven; the study cannot establish causation.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 agonist. Retatrutide adds a third target: it is a triple agonist of the GIP, GLP-1, and glucagon receptors, the only tri-agonist in clinical development for obesity. The glucagon component is the key pharmacological difference and is the leading candidate explanation for why its self-reported symptom profile — concentrated in appetite, energy, sleep, and heart-rate categories — diverges from the nausea-and-vomiting-dominated profile reported for semaglutide and tirzepatide in the same researchers' prior Reddit work.

Is retatrutide approved or legal to buy?

Retatrutide is investigational. As of mid-2026 it has not been approved by the FDA or any major regulator; phase 3 trials are ongoing. The FDA issued a warning in February 2026 about unapproved GLP-1 products, including retatrutide, sold directly to consumers, often labeled for research or not for human consumption. The products discussed in the Reddit study are gray-market, meaning their identity, purity, dose, and sterility are unverified. There is no approved human therapeutic product, and the safety data in this real-world population does not exist outside of analyses like this one.

Can you trust side-effect data scraped from Reddit?

It is a real signal but a biased one. The study used a large language model validated against manual review — 94.4% precision for identifying self-reported use and 91.0% precision for extracting symptoms — so the extraction is reasonably accurate. But Reddit users are not a representative sample of all retatrutide users, people who experience side effects are more likely to post, and the analysis cannot determine product identity, dose, purity, or whether a symptom was caused by retatrutide, by a co-administered peptide, or by something unrelated. The authors are explicit that the work is hypothesis-generating and warrants formal pharmacovigilance, not a substitute for it.

What are the most important warning signs to watch for on retatrutide?

Beyond the commonly reported nuisance symptoms, the signals that warrant stopping and seeking medical evaluation include a sustained resting heart rate increase or palpitations, signs of pancreatitis such as severe persistent abdominal pain radiating to the back with vomiting, symptoms of dehydration from prolonged vomiting or diarrhea, and any signs of an allergic reaction. Because gray-market product carries unknown purity and the glucagon component can affect glucose and cardiovascular parameters, anyone with diabetes, cardiovascular disease, or on other medications faces compounded and poorly characterized risk. This compound is not approved for human use and carries no established safety margin in this population.